How should we define disease modification in MF?

During the ESH 9th Translational Research Conference: Myeloproliferative Neoplasms, the MPN Hub was pleased to speak to Naveen Pemmaraju, MD Anderson Cancer Center, Houston, US. We asked, How should we define disease modification in myelofibrosis (MF)?

Pemmaraju begins by explaining that since there is currently only one approved drug class for MF treatment (JAK inhibitors), the outcomes for patients can be variable. Pemmaraju goes on to discuss the importance of measuring disease, and how the introduction of new combination therapies could lead to new response criteria. Finally, Pemmaraju talks about a review article published in 'Cancer' earlier this year (2022), led by himself and Professor Adam J. Mead, University of Oxford, Oxford, UK.